Prospects of radioimmunotherapy in epithelial ovarian cancer: Results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies

Gynecologic Oncology

Volumn 67, Issue 3, 1997, Pages 259-271

  Juweid, Malik ^a,c   Swayne, Lawrence C ^a   Sharkey, Robert M ^a   Dunn, Robert ^a   Rubin, Arnold D ^b   Herskovic, Thomas ^b   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

^c GARDEN STATE CANCER CENTER   (United States)

Author keywords

CEA (carcinoembryonic antigen); Epithelial ovarian cancer; Radioimmunotherapy; Radiolabeled monoclonal antibody; Targeting

Indexed keywords

CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY MN 14; IMMU 14; IODINE 131; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; GYNECOLOGIC CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SCINTIGRAPHY;

EID: 0031441352     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4870     Document Type: Article

References (29)

1. 1. Epenetos AA, Munro AJ, Stewart S, Rampling R, Lambert HE, McKenzie CG, Soutter P, Rahemetulla A, Hooker G, Sivolapenko GB, Snook D, Courtenay-Luck N, Dhokia B, Krausz T, Taylor-Papadimitriou J, Durbin H, Bodmer WF: Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 5:1890-1899, 1987
2. 2. Finkler NJ, Muto MG, Kassis AI, Weadock K, Sabah ST, Zurawski VR Jr, Knapp RC: Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer. Gynecol Oncol 34:339-344, 1989
3. 3. Breitz HB, Fisher DR, Weiden PL, Durham JS, Ratliff BA, Bjorn MJ, Beaumier PL, Abrams PG: Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials. J Nucl Med 34:908-917, 1993
4. 4. Stewart JSW, Hird V, Snook D, Dhokia B, Sivolapenko G, Hooker G, Taylor-Papadimitriou J, Rowlinson G, Sullivan M, Lambert HE, Coulter C, Mason WP, Soutter WP, Epenetos AA: Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 8:1941-1950, 1990
5. 5. Di Saia PJ, Morrow CP, Haverback BJ, Dyce BJ: Carcinoembryonic antigen in cancer of the female reproductive system. Serial plasma values correlated with disease state. Cancer 39:2365-2370, 1977
6. 6. Van Nagell JR, Kim E, Casper S, Primus FJ, Bennett S, DeLand FH, Goldenberg DM: Radioimmunodetection of primary and metastatic ovarian cancer using radiolabeled antibodies to carcinoembryonic antigen. Cancer Res 40:502-506, 1980
7. 7. Hansen HJ, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM: Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer 71:3478-3485, 1993
8. 8. Sharkey RM, Goldenberg DM, Murthy S, Pinsky H, Vagg R, Pawlyk D, Siegel JA, Wong GY, Gascon P, Izon DO, Vezza M, Burger K, Swayne LC, Pincksy CM, Hansen HJ: Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 71:2082-2096, 1993
9. 2. Cancer 78:157-168, 1996
10. 10. Sharkey RM, Juweid M, Shevitz J, Behr T, Dunn R, Swayne LC, Wong GY, Blumenthal RD, Griffiths GL, Siegel JA, Leung SO, Hansen HJ, Goldenberg DM: Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res 55:5935s-5945s, 1995
11. 11. Hoffman T: Points to consider in the manufacture and testing of monoclonal antibody products for human use. Memorandum from Office of Biologies Research and Review, Center for Drugs and Biologies, Food and Drug Administration, 1987
12. 12. Weadock KS, Sharkey RM, Varga DC, Goldenberg DM: Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 31: 508-511, 1989
13. 13. Siegel JA, Pawlyk DA, Lee RE, Sharkey RM, Horowitz J, Goldenberg DM: Tumor, red marrow, and organ dosimetry for 1311-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res 50:1039-1042, 1990
14. 14. Siegel JA, Goldenberg DM, Sharkey RM, Hall TC, Murthy S, Lee RE, Pawlyk DA, Swayne LC: Tumor and organ dosimetry for I-131-labeled LL2 (EPB-2) monoclonal antibody in patients with B-cell lymphomas. Antib Immunoconj Radiopharm 4:649-654, 1991
15. 15. Snyder WS, Ford MR, Warner GG, Watson SB: "S" absorbed dose per unit cumulative activity for selected radionuclides and organs. MIRD Pamphlet No. 11, New York: Society of Nuclear Medicine, 1975
16. 16. Sgouros G: Bone marrow dosimetry for radioimmunotherapy. Theoretical considerations. J Nucl Med 34:689-694, 1993
17. 17. Hansen HJ, Sullivan CL, Sharkey RM, Goldenberg DM: HAMA interference with murine monoclonal antibody-based immunoassays. J Clin Immunoassay 16:294-299, 1993
18. 18. Ward BG, Mather SJ, Hawkins LR, Crowther ME, Shepherd JH, Granowska M, Britton KE, Slevin ML: HMFG 2 in human ovarian carcinoma: Assessment of intravenous and intraperitoneal routes of administration. Cancer Res 47:4719, 1987
19. 19. Larson SM, Leibel SA, Cheung NKV: Radioisotope Conjugates, in DeVita VT Jr, Hellman S, Rosenberg SA, (eds): Biologic Therapy of Cancer. Philadelphia, PA, Lippincott, pp. 496-511, 1991
20. 20. Goldenberg DM: Monoclonal antibodies in cancer detection therapy. Am J Med 94:297-312, 1993
21. 21. Chatal JF, Saccavini JC, Thedres P, Curtet C, Kremer M, Guerreau D, Nolibe D, Fumoleau P, Guillard Y: Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients with ovarian cancer. Cancer Res 49:3087-3094, 1989
22. 22. Hagan PI, Halpern SE, Dillman RO, Shawler DL, Johnson DE, Chen A, Krishnan L, Frincke J, Bartholomew RM, David GS, Carlo D: Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med 27:422-427, 1986
23. 23. Juweid M, Sharkey RM, Alavia A, Swayne LC, Herskovic T, Hanley D, Rubin AD, Pereira M, Goldenberg DM: Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody. J Nucl Med 38:257-260, 1997
24. 24. Potter ME, Partridge EE, Shingleton HM, Soong S-J, Kim RY, Hatch KD, Austin JM Jr: Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits. Gynecol Oncol 32:314-318, 1989
25. 25. Pezner RD, Stevens KR Jr, Tong D, Allen CV: Limited epithelial carcinoma of the ovary treated with curative intent by the intraperitoneal installation of radiocolloids. Cancer 42:2563-2571, 1978
26. 26. Kosmas C, Epenetos AA, Courtenay-Luck NS: Patients receiving murine monoclonal antibody therapy develop T cells that proliferate in vitro in response to these antibodies as antigens. Br J Cancer 64:494-500, 1991
27. 27. Courtenay-Luck NS, Epenetos AA, Sivolapenko GB, Moore R, Larche M, Pectasides D, Dhokia B, Ritter MA: Development of anti-idiotypic antibodies against tumor antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet ii, 894-897, 1988
28. 28. Baum RP, Niesen A, Hertel A, Nancy A, Hess H, Donnerstag B, Sykes TR, Sykes CJ, Suresh MR, Noujaim AA, Hör G: Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer (Suppl) 73:1121-1125, 1994
29. 29. Wagner U, Oehr P, Reinberg J: Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network. Biotechnol Ther 3:81-89, 1992